VISCHER advises Proteomedix with the creation of Onconetix

Proteomedix, a Swiss private, commercial-stage diagnostics oncology company and Water Biotech are forming together a company called Onconetix. The transaction is implemented by the acquisition of Proteomedix for an all stock consideration. Onconetix’s commercial products are Entadfi®, an FDA-approved, once-daily oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), and Proclarix®, a European CE IVD approval for prostate diagnostics and a lab developed test (LDT) currently in the U.S., originally developed by Proteomedix.

VISCHER is advising Proteomedix on all Swiss law matters of the transaction with a team consisting of partner Matthias Staehelin (pictured), associate Timothy Woodtli and junior associate Benjamin Sarasin (all Corporate).